This company has been acquired
Emerald Health Therapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
-21.1%
Earnings growth rate
-12.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 29.1% |
| Return on equity | -101.2% |
| Net Margin | -395.3% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Emerald Health Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 7 | -28 | 11 | 1 |
| 31 Mar 22 | 9 | -40 | 11 | 2 |
| 31 Dec 21 | 10 | -39 | 11 | 2 |
| 30 Sep 21 | 10 | -34 | 12 | 2 |
| 30 Jun 21 | 12 | -36 | 12 | 2 |
| 31 Mar 21 | 11 | -41 | 12 | 1 |
| 31 Dec 20 | 12 | -43 | 14 | 2 |
| 30 Sep 20 | 13 | -125 | 15 | 2 |
| 30 Jun 20 | 19 | -131 | 20 | 3 |
| 31 Mar 20 | 21 | -112 | 28 | 4 |
| 31 Dec 19 | 20 | -111 | 30 | 4 |
| 30 Sep 19 | 17 | -35 | 39 | 4 |
| 30 Jun 19 | 8 | -24 | 40 | 3 |
| 31 Mar 19 | 4 | -29 | 35 | 2 |
| 31 Dec 18 | 2 | -31 | 33 | 1 |
| 30 Sep 18 | 1 | -21 | 25 | 0 |
| 30 Jun 18 | 1 | -16 | 17 | 0 |
| 31 Mar 18 | 1 | -12 | 12 | 0 |
| 31 Dec 17 | 1 | -9 | 8 | 0 |
| 30 Sep 17 | 1 | -6 | 5 | 0 |
| 30 Jun 17 | 1 | -5 | 4 | 0 |
| 31 Mar 17 | 0 | -4 | 3 | 0 |
| 31 Dec 16 | 0 | -3 | 2 | 0 |
| 30 Sep 16 | 0 | -3 | 2 | 0 |
| 30 Jun 16 | 0 | -2 | 2 | 0 |
| 31 Mar 16 | 0 | -3 | 3 | 0 |
| 31 Dec 15 | 0 | -3 | 3 | 0 |
Quality Earnings: EMHT.F is currently unprofitable.
Growing Profit Margin: EMHT.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EMHT.F is unprofitable, and losses have increased over the past 5 years at a rate of 21.1% per year.
Accelerating Growth: Unable to compare EMHT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EMHT.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.8%).
Return on Equity
High ROE: EMHT.F has a negative Return on Equity (-101.23%), as it is currently unprofitable.